MIRA (Mira Pharmaceuticals) Non Operating Income: $-0.23 Mil (TTM As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

MIRA Mira Pharmaceuticals Inc MIRA
26 GF Score
Price $0.79
! 1 Warning Sign
View Full Analysis

What is Mira Pharmaceuticals Non Operating Income?

Mira Pharmaceuticals MIRA -1.96% 26 Non Operating Income is $-0.23 Mil as of Jun. 2026. GuruFocus rates MIRA with a GF Score™ of 26/100. The stock has 1 warning sign investors should review.

Non Operating Income is income or expense that comes from miscellaneous sources. Mira Pharmaceuticals's Non Operating Income for the three months ended in Jun. 2026 was $-0.09 Mil. Its Non Operating Income for the trailing twelve months (TTM) ended in Jun. 2026 was $-0.23 Mil.

Mira Pharmaceuticals Non Operating Income Related Terms

Mira Pharmaceuticals Non Operating Income Historical Data

* Premium members only.

The historical data trend for Mira Pharmaceuticals's Non Operating Income can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Mira Pharmaceuticals Non Operating Income Chart

Mira Pharmaceuticals Annual Data
Trend Dec21 Dec22 Dec23 Dec24 Dec25
Non Operating Income
0.00 0.00 0.00 0.00 -0.05

Mira Pharmaceuticals Quarterly Data
Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Non Operating Income Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.16 -0.21 -0.09 -0.09
MIRA
26GF Score
Mira Pharmaceuticals Inc MIRA
Non Operating Income is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Mira Pharmaceuticals Non Operating Income Calculation

Non Operating Income is income or expense that comes from miscellaneous sources.

Non Operating Income for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.23 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Non Operating Income →
What does a Non Operating Income of $-0.23 Mil mean?
Mira Pharmaceuticals (MIRA) has a Non Operating Income of $-0.23 Mil as of Jun. 2026. Non-operating Income represents the amount of income from one-time, nonrecurring events. View historical data on Mira Pharmaceuticals and its competitors.
Is Mira Pharmaceuticals' Non Operating Income too high?
Mira Pharmaceuticals' current Non Operating Income is $-0.23 Mil. Overall, Mira Pharmaceuticals has a GF Score™ of 26/100, reflecting its overall financial health beyond just this single metric.
How does Mira Pharmaceuticals' Non Operating Income compare to SCLX and MDCX?
Mira Pharmaceuticals' Non Operating Income of $-0.23 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Non Operating Income for a Drug Manufacturers company?
A good Non Operating Income depends on the Drug Manufacturers industry context. However, Non Operating Income should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Non Operating Income mean?
A high Non Operating Income can signal that a stock is expensive relative to its fundamentals. Non-operating Income represents the amount of income from one-time, nonrecurring events. View historical data on Mira Pharmaceuticals and its competitors. Mira Pharmaceuticals's current Non Operating Income is $-0.23 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Mira Pharmaceuticals stock overvalued right now?
Mira Pharmaceuticals (MIRA) has a current Non Operating Income of $-0.23 Mil. The current Non Operating Income is $-0.23 Mil. Mira Pharmaceuticals' overall GF Score™ is 26/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Non Operating Income calculated?
Non Operating Income is calculated from a company's financial statements. For Mira Pharmaceuticals (MIRA), the current Non Operating Income is $-0.23 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Mira Pharmaceuticals Business Description

Other Exchanges K6S:Germany
Address 1200 Brickell Avenue, Suite 1950 No. 1183, Miami, FL, USA, 33133
Mira Pharmaceuticals Inc is a clinical-stage pharmaceutical development company focused on developing novel oral small-molecule therapeutics for neurologic, neuropsychiatric, metabolic, and inflammatory disorders. The company's pipeline includes three product candidates: Ketamir-2, MIRA-55, and SKNY-1, three drug candidates designed to address unmet medical needs across neuropathic and inflammatory pain, central nervous system disorders, and metabolic and behavioral conditions. The company operates as a single operating and reportable segment.
26GF Score

Get the complete analysis for MIRA

Non Operating Income is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.79
Price